Medicine
Metabolic Bone Disease in Preterm Infants
Quick fact
Metabolic bone disease affects up to 30% of very low birth weight preterm infants, and many cases show no symptoms until a routine X-ray reveals fractures or demineralization.
Why this is interesting
Imagine a baby whose bones are so fragile that merely being picked up can cause a fracture. This is a real risk for some premature infants, and it's not because of a rare genetic disease—it's due to a silent mineral deficiency that often goes unnoticed until it's too late.
Read the full explanation
Understanding Metabolic Bone Disease in Preterm Infants
During the last trimester of pregnancy, a fetus typically receives the majority of its calcium and phosphorus from the mother, building up strong bones. A preterm infant is born before this critical mineral accumulation occurs. After birth, the baby needs to receive these minerals through nutrition, but common feeding methods—like unfortified breast milk or standard formula—may not provide enough. Without sufficient calcium and phosphorus, the body's bone-building 'construction crew' lacks its essential raw materials, leading to bones that are poorly mineralized and weak. This condition is what we call metabolic bone disease (MBD) of prematurity.
A deeper explanation
The underlying driver is a mismatch between the infant's rapid growth rate and mineral supply. New bone matrix is continuously laid down, but if calcium and phosphorus are scarce, the matrix cannot be properly mineralized. The kidneys also play a role, as they reabsorb phosphate. In premature infants, this reabsorption is immature, causing excessive phosphate loss in the urine. This worsens the imbalance. Consequently, blood phosphorus levels drop, and the body attempts to compensate by pulling minerals from bone, leading to a rise in alkaline phosphatase—a marker of bone turnover. If MBD is severe, fractures can occur, sometimes during routine handling. Early detection through biochemical screening (e.g., low serum phosphate, high alkaline phosphatase) allows for intervention, such as fortifying milk with additional minerals or using specialized preterm formulas. Without adequate treatment, the condition can persist and affect long-term bone health.